State Key Laboratory of Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, P. R. China.
ACS Appl Mater Interfaces. 2021 May 5;13(17):19648-19659. doi: 10.1021/acsami.1c01943. Epub 2021 Apr 23.
A "closed-loop" insulin delivery system that can mimic the dynamic and glucose-responsive insulin secretion as islet β-cells is desirable for the therapy of type 1 and advanced type 2 diabetes mellitus (T1DM and T2DM). Herein, we introduced a kind of "core-shell"-structured glucose-responsive nanoplatform to achieve intravenous "smart" insulin delivery. A finely controlled one-pot biomimetic mineralization method was utilized to coencapsulate insulin, glucose oxidase (GOx), and catalase (CAT) into the ZIF-8 nanoparticles (NPs) to construct the "inner core", where an efficient enzyme cascade system (GOx/CAT group) served as an optimized glucose-responsive module that could rapidly catalyze glucose to yield gluconic acid to lower the local pH and effectively consume the harmful byproduct hydrogen peroxide (HO), inducing the collapse of pH-sensitive ZIF-8 NPs to release insulin. The erythrocyte membrane, a sort of natural biological derived lipid bilayer membrane which has intrinsic biocompatibility, was enveloped onto the surface of the "inner core" as the "outer shell" to protect them from elimination by the immune system, thus making the NPs intravenously injectable and could stably maintain a long-term existence in blood circulation. The and results indicate that our well-designed nanoplatform possesses an excellent glucose-responsive property and can maintain the blood glucose levels of the streptozocin (STZ)-induced type 1 diabetic mice at the normoglycemic state for up to 24 h after being intravenously administrated, confirming an intravenous insulin delivery strategy to overcome the deficits of conventional daily multiple subcutaneous insulin administration and offering a potential candidate for long-term T1DM treatment.
一种能够模拟胰岛β细胞动态和葡萄糖响应性胰岛素分泌的“闭环”胰岛素输送系统,是治疗 1 型和 2 型糖尿病(T1DM 和 T2DM)的理想选择。在此,我们引入了一种“核壳”结构的葡萄糖响应性纳米平台,以实现静脉内“智能”胰岛素输送。采用精细控制的一锅仿生矿化方法将胰岛素、葡萄糖氧化酶(GOx)和过氧化氢酶(CAT)共包封到 ZIF-8 纳米颗粒(NPs)中,构建“内芯”,其中高效酶级联系统(GOx/CAT 组)作为优化的葡萄糖响应模块,可以快速催化葡萄糖生成葡萄糖酸,降低局部 pH 值,并有效消耗有害副产物过氧化氢(HO),诱导 pH 敏感的 ZIF-8 NPs 崩溃,从而释放胰岛素。红细胞膜是一种天然的生物衍生脂质双层膜,具有内在的生物相容性,被包裹在“内芯”的表面作为“外壳”,以保护它们免受免疫系统的清除,从而使 NPs 能够静脉注射,并能够在血液循环中稳定地长期存在。和结果表明,我们设计良好的纳米平台具有出色的葡萄糖响应性能,并能够在静脉注射后长达 24 小时将链脲佐菌素(STZ)诱导的 1 型糖尿病小鼠的血糖水平维持在正常水平,证实了一种静脉内胰岛素输送策略,可以克服传统每日多次皮下胰岛素注射的缺陷,为长期 1 型糖尿病治疗提供了潜在的候选药物。